Delivering Value To Those We Serve

Overview

Recent News

Date Title and Summary
Toggle Summary Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products
Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million , Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive Chairman and Todd
Toggle Summary Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024
LAKE FOREST, Ill. , March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal amount of its 2.50%
Toggle Summary Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results
  -- Reports Neurology Franchise Annual Net Sales of $108.1 Million , Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA ® Franchise and Gralise ®  Totaling $502.5 Million -- -- Repaid in Full Senior Secured Debt and Reduced Convertible Debt by $188.0 Million --

Upcoming Events

There are currently no events to display.

Recent SEC Filings

Filing date Description Form Filing Group View

Optional form for the registration of securities to be sold to the public by small business issuers

SB-2
Registration Statements
View HTML

Pre-effective amendment to an SB-2 filing

SB-2/A
Registration Statements
View HTML

Registration of certain classes of securities 12(b) of the Securities Exchange Act

8-A12B
Registration Statements
View HTML

Substantive changes from or additions to a prospectus previously filed

424A
Registration Statements
View HTML

Pre-effective amendment to an SB-2 filing

SB-2/A
Registration Statements
View HTML

IR Contact

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
Phone: 800.509.5586
http://www.continentalstock.com
 

Independent Registered Public Accounting Firm

Ernst & Young LLP
Palo Alto, CA
 

Investor Relations Contact

investor@assertiotx.com